CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex

Markênia Kélia Santos Alves1, Mário Henrique Girão Faria, Eduardo Henrique Cunha Neves Filho

  • 1Universidade Federal do Ceará, Department of Pathology and Forensic Medicine, Rua Alexandre Baraúna, 949, Porangabussu, CEP 60183-630 Fortaleza, Brazil. markenialves@yahoo.com.br

Insights

CDKN2A promoter methylation frequently inactivates the CDKN2A gene in astrocytomas. This epigenetic alteration correlates with patient age and sex, impacting p16(INK4A) protein expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • CDKN2A (p16(INK4A)) inactivation is common in astrocytomas.
  • The precise mechanism of CDKN2A alteration in astrocytomas remains debated.
  • Promoter hypermethylation is a known cancer-related epigenetic modification.

Purpose of the Study:

  • To investigate the association between CDKN2A promoter methylation and p16(INK4A) expression in astrocytomas.
  • To correlate CDKN2A methylation status with tumor grade and clinicopathological parameters.
  • To elucidate the role of CDKN2A promoter methylation in astrocytoma pathogenesis.

Main Methods:

  • Analysis of 93 astrocytic tumors (WHO grades I-IV) using formalin-fixed paraffin-embedded tissue.
  • CDKN2A promoter methylation assessed via methylation-specific PCR.
  • p16(INK4A) protein expression evaluated by immunohistochemistry.

Main Results:

  • A strong negative correlation was observed between CDKN2A promoter methylation and p16(INK4A) expression (nuclear and cytoplasmic).
  • CDKN2A promoter methylation showed a significant negative correlation with patient age.
  • Female patients exhibited a higher frequency of CDKN2A methylated promoters compared to male patients (p=0.036).

Conclusions:

  • CDKN2A inactivation via promoter methylation is a frequent event in astrocytomas.
  • Patient age and sex are significant factors associated with CDKN2A promoter methylation in astrocytomas.
  • Epigenetic silencing of CDKN2A contributes to astrocytoma development and progression.